Sponsored content
Oct. 15, 2020
Following Johnson & Johnson Vision’s recent FDA Breakthrough Device Designation for its myopia control lens, Review of Myopia Management’s John Sailer interviewed Noel Brennan, BOptom, MScOptom, PhD, FAAO, research fellow at Johnson & Johnson Vision, to find out the company’s plans for its role in myopia management, its approach to merging the science with patient care and to ask for any clues on what’s in the pipeline.
